ArticleFoods (Basel, Switzerland)2026
Unravelling the Interaction Mechanism Between Oryzanol and Human Serum Albumin: An Integrated Approach Using Multispectral Analysis and Molecular Simulations.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gamma-oryzanol (Ory), a major bioactive constituent of rice bran oil, has attracted increasing attention because of its antioxidant and cholesterol-lowering properties. In this study, the interactions between Ory and human serum albumin (HSA) and the underlying molecular mechanisms were investigated. The quenching of HSA fluorescence by Ory occurred via a mixed mechanism, indicating the formation of a stable complex. Thermodynamic analyses and molecular dynamics showed that the HSA-Ory complex was stabilised primarily by hydrogen bonding and van der Waals interactions. Moreover, competitive site marker experiments, complemented by molecular docking and MM-PBSA calculations revealed that Ory specifically targets site I of HSA, engaging in stable interactions with critical residues such as Trp214 and Lys199. Additionally, the dissociation behaviour of Ory was explored using steered molecular dynamics simulations, highlighting the role of specific amino acid residues in regulating the dissociation of Ory from HSA site I. Overall, this study provided molecular insights into the binding mechanisms and interactions between HSA and Ory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.